X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ORCHID PHARMA LTD NATCO PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 16.0 0.1 11,032.4% View Chart
P/BV x 17.2 0.2 10,046.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 NATCO PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ORCHID PHARMA LTD
Sep-13
NATCO PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs877194 452.1%   
Low Rs42435 1,210.0%   
Sales per share (Unadj.) Rs223.4276.5 80.8%  
Earnings per share (Unadj.) Rs31.1-79.2 -39.2%  
Cash flow per share (Unadj.) Rs40.3-43.5 -92.7%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.553.9 406.9%  
Shares outstanding (eoy) m33.0770.45 46.9%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.90.4 702.7%   
Avg P/E ratio x20.9-1.4 -1,447.9%  
P/CF ratio (eoy) x16.1-2.6 -612.7%  
Price / Book Value ratio x3.02.1 139.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5048,067 266.6%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,1282,527 44.6%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m7,38919,477 37.9%  
Other income Rs m167407 41.0%   
Total revenues Rs m7,55619,884 38.0%   
Gross profit Rs m1,7931,103 162.6%  
Depreciation Rs m3042,519 12.1%   
Interest Rs m3665,227 7.0%   
Profit before tax Rs m1,290-6,236 -20.7%   
Minority Interest Rs m4620 235.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m309-125 -246.6%   
Profit after tax Rs m1,027-5,580 -18.4%  
Gross profit margin %24.35.7 428.7%  
Effective tax rate %23.92.0 1,192.1%   
Net profit margin %13.9-28.7 -48.5%  
BALANCE SHEET DATA
Current assets Rs m3,68111,014 33.4%   
Current liabilities Rs m3,12332,060 9.7%   
Net working cap to sales %7.6-108.1 -7.0%  
Current ratio x1.20.3 343.1%  
Inventory Days Days8995 94.3%  
Debtors Days Days5934 174.9%  
Net fixed assets Rs m7,68529,440 26.1%   
Share capital Rs m331705 46.9%   
"Free" reserves Rs m6,6702,043 326.5%   
Net worth Rs m7,2593,800 191.0%   
Long term debt Rs m9559,018 10.6%   
Total assets Rs m11,95746,510 25.7%  
Interest coverage x4.5-0.2 -2,341.6%   
Debt to equity ratio x0.12.4 5.5%  
Sales to assets ratio x0.60.4 147.6%   
Return on assets %11.7-0.8 -1,533.5%  
Return on equity %14.2-146.9 -9.6%  
Return on capital %20.7-3.7 -554.9%  
Exports to sales %39.437.9 103.9%   
Imports to sales %5.722.6 25.2%   
Exports (fob) Rs m2,9087,378 39.4%   
Imports (cif) Rs m4214,406 9.6%   
Fx inflow Rs m3,4457,513 45.9%   
Fx outflow Rs m7035,649 12.4%   
Net fx Rs m2,7431,865 147.1%   
CASH FLOW
From Operations Rs m1,4401,682 85.6%  
From Investments Rs m-1,089-9,860 11.0%  
From Financial Activity Rs m-3536,644 -5.3%  
Net Cashflow Rs m-1-1,535 0.1%  

Share Holding

Indian Promoters % 52.0 32.3 161.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.6 170.4%  
FIIs % 16.6 3.3 503.9%  
ADR/GDR % 0.0 4.6 -  
Free float % 26.0 55.3 47.0%  
Shareholders   25,395 84,811 29.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 16, 2018 03:05 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS